FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Arceci

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Physiology

Drug Resistance

Co-author Network

Publications

TOP 3
Margaret E Macy; Aru Narendren; Katherine Rolla; Tanya Trippett; James Whitlock; Robert J Arceci; Rochelle Bagatell; Jessica Boklan; Uwe Christians; Tracey Duncan; Lia Gore; Cynthia Herzog; Stephen P Hunger; S Percy Ivy
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Abeer Abd Elmoneim; Jessica Boklan; Todd Cooper; Lia Gore; Aru Narendran; Rebecca M Ricklis; Katherine Rolla; Tammy Scott; Robert J Arceci
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Gitanjali I Bechan; R Maarten Egeler; Wilfred T V Germeraad; Diana Heckel; Anna M Kruisbeek; David W Lee; Mark Throsby; Marja Van Meijer; Rena Xian; Dirk Zajonc; Robert J Arceci
Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Arceci (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Margaret E Macy; Aru Narendren; Katherine Rolla; Tanya Trippett; James Whitlock; Robert J Arceci; Rochelle Bagatell; Jessica Boklan; Uwe Christians; Tracey Duncan; Lia Gore; Cynthia Herzog; Stephen P Hunger; S Percy Ivy
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Pediatric blood & cancer 2013;60(2):230-6.
2012: Abeer Abd Elmoneim; Jessica Boklan; Todd Cooper; Lia Gore; Aru Narendran; Rebecca M Ricklis; Katherine Rolla; Tammy Scott; Robert J Arceci
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Pediatric blood & cancer 2012;59(7):1252-8.
2012: Gitanjali I Bechan; R Maarten Egeler; Wilfred T V Germeraad; Diana Heckel; Anna M Kruisbeek; David W Lee; Mark Throsby; Marja Van Meijer; Rena Xian; Dirk Zajonc; Robert J Arceci
Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.
British journal of haematology 2012;159(3):299-310.
2012: April D Sorrell; Jeffrey W Taub; William G Woods; Todd A Alonzo; Robert J Arceci; Dorothy Barnard; Robert B Gerbing; Lois Hathaway; Joanne M Hilden; Thomas W Loew; Yaddanapudi Ravindranath; Franklin O Smith; Alan S Gamis
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Cancer 2012;118(19):4806-14.
2012: Nobuko Hijiya; Elly Barry; Robert J Arceci
Clofarabine in pediatric acute leukemia: current findings and issues.
Pediatric blood & cancer 2012;59(3):417-22.
2012: Janine R Hutson; Richard B Kim; Tal Schechter; Sheila Weitzman; Robert J Arceci; Yaron Finkelstein
Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.
Expert opinion on drug metabolism & toxicology 2012;8(6):709-22.
2012: Chad M McCall; Shiyama Mudali; Donald Small; Milena Vuica; Robert J Arceci; Michael J Borowitz; Kathleen HELEN Burns; Shirley Fuller; Christopher D Gocke; Amy S Duffield
Flow cytometric findings in hemophagocytic lymphohistiocytosis.
American journal of clinical pathology 2012;137(5):786-94.
2012: Todd M Cooper; James Feusner; Janet Franklin; Todd A Alonzo; Robert J Arceci; Robert B Gerbing; Betsy Hirsch; Craig Hurwitz; Robert Iannone; Robert S Lavey; Prasad Mathew; Soheil Meshinchi; Susana C Raimondi; Franklin O Smith; Alan Gamis
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cancer 2012;118(3):761-9.
2011: JASON FARRAR; Hannah Carlson-Donohoe; Steven R Ellis; Eva Atsidaftos; Robert J Arceci; Adrianna Vlachos; Thomas C Markello; Jeffrey M Lipton; David M Bodine
Ribosomal protein gene deletions in Diamond-Blackfan anemia.
Blood 2011;118(26):6943-51.
2011: Alan S Gamis; Joanne M Hilden; Jeffrey W Taub; April D Sorrell; Dorothy Barnard; Mukta Sharma; John Perentesis; John Doyle; Yaddanapudi Ravindranath; Robert J Arceci; Todd A Alonzo; Gita Massey; Robert B Gerbing; Thomas W Loew; Franklin O Smith
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Blood 2011;118(26):6752-9; quiz 6996.
2011: Prasad Mathew; Susana C Raimondi; Franklin O Smith; Tanya Wallas; Todd A Alonzo; Cathy M Chavez; Nancy L Eisenberg; Alan Gamis; Robert B Gerbing; Jerald Z Gong; Betsy Hirsch; Rama Jasty; Dean T Jorstad; Robert J Arceci
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121).
Pediatric blood & cancer 2011;57(7):1230-2.
2011: Martin A Champagne; Cecilia H Fu; Myron Chang; Helen Chen; Robert B Gerbing; Todd A Alonzo; Linda D Cooley; Nyla A Heerema; Vivian Oehler; Charlotte Wood; Mary Ellen French; Robert J Arceci; Franklin O Smith; Mark L Bernstein
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
Pediatric blood & cancer 2011;57(1):56-62.
2011: Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):551-65.
2011: BRIGITTE WIDEMANN; Robert J Arceci; Nalini Jayaprakash; Elizabeth Fox; Peter Zannikos; Wendy Goodspeed; Anne Goodwin; John J Wright; Susan M Blaney; Peter Charles Adamson; FRANK BALIS
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Pediatric blood & cancer 2011;56(2):226-33.
2011: Elisabeth F Heuston; Kenya T Lemon; Robert J Arceci
The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies.
Frontiers in genetics 2011;2():94.
2011: Kimberley A Hoeksema; Aarthi Jayanthan; Tanya Trippett; Robert J Arceci; Jessica Boklan; Todd Cooper; Lia Gore; Aru Narendran
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.
OncoTargets and therapy 2011;4():149-68.
2010: Kim E Nichols; Robert J Arceci
BRAF, a piece of the LCH puzzle.
Blood 2010;116(11):1825-7.
2010: Terzah M Horton; Richard Sposto; Patrick Brown; Charles Patrick Reynolds; Stephen P Hunger; Naomi J Winick; Elizabeth A Raetz; William L Carroll; Robert J Arceci; Michael J Borowitz; Paul S Gaynon; Lia Gore; Sima Jeha; Barry J Maurer; Stuart E Siegel; Andrea Biondi; Pamela R Kearns; Aru Narendran; Lewis B Silverman; Malcolm A Smith; C Michel Zwaan; James A Whitlock
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Pediatric blood & cancer 2010;54(7):872-8.
2010: Nicole Grois; Bernhard Fahrner; Robert J Arceci; Jan-Inge Henter; Kenneth McClain; Hans Lassmann; Vasanta Nanduri; Helmut Prosch; Daniela Prayer
Central nervous system disease in Langerhans cell histiocytosis.
The Journal of pediatrics 2010;156(6):873-81, 881.e1.
2010: Maureen M O'Brien; Norman J Lacayo; Bert L Lum; Smita Kshirsagar; Steven Buck; Yaddanapudi Ravindranath; Mark Bernstein; Howard Weinstein; Myron N Chang; Robert J Arceci; Branimir I Sikic; Gary V Dahl
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Pediatric blood & cancer 2010;54(5):694-702.
2010: Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix Anh-Dung Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood 2010;115(12):2372-9.
2010: Steven D Gore; Ivana Gojo; Mikkael A Sekeres; Lawrence Morris; Marcel Devetten; Katarzyna Jamieson; Robert L Redner; Robert J Arceci; Ibitayo Owoeye; Tianna Dauses; Esther Schachter-Tokarz; Robert E Gallagher
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(6):1047-53.
2010: Bella S Guerrouahen; Muneyoshi Futami; Christos Vaklavas; Jukka Kanerva; Zakary L Whichard; Kenechi Nwawka; Elisabeth G Blanchard; Francis Y Lee; Lisa J Robinson; Robert J Arceci; Steven M Kornblau; Eric Wieder; Yvon E Cayre; Seth J Corey
Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1149-58.
2010: Leana Doherty; Mee Rie Sheen; Adrianna Vlachos; Valerie Choesmel; Marie-Françoise O'Donohue; Catherine Clinton; Hal E Schneider; Colin A Sieff; Peter E Newburger; Sarah E Ball; Edyta Niewiadomska; Michal Matysiak; Bertil E Glader; Robert J Arceci; JASON FARRAR; Eva Atsidaftos; Jeffrey Lipton; Pierre-Emmanuel Gleizes; Hanna T Gazda
Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.
American journal of human genetics 2010;86(2):222-8.
2010: Shilpa Jain; Norma Kanarek; Robert J Arceci
Analysis of histiocytosis deaths in the US and recommendations for incidence tracking.
Journal of registry management 2010;37(4):156-62.
2010: Philipp Kapranov; Georges St Laurent; Tal Raz; Fatih Ozsolak; Charles Patrick Reynolds; Poul H B Sorensen; Gregory Reaman; Patrice Milos; Robert J Arceci; John F Thompson; Timothy Triche
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA.
BMC biology 2010;8():149.
2010: Joseph Brady Moore; JASON FARRAR; Robert J Arceci; Johnson Ming-Yu Liu; Steven R Ellis
Distinct ribosome maturation defects in yeast models of Diamond-Blackfan anemia and Shwachman-Diamond syndrome.
Haematologica 2010;95(1):57-64.
2009: Sheila Weitzman; Jorge Braier; jean donadieu; R Maarten Egeler; Nicole Grois; Stephan Ladisch; Ulrike Pötschger; David Webb; James Whitlock; Robert J Arceci
2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Pediatric blood & cancer 2009;53(7):1271-6.
2009: Suzie A Noronha; JASON FARRAR; Todd A Alonzo; Robert B Gerbing; Norman J Lacayo; Gary V Dahl; Yaddanapudi Ravindranath; Robert J Arceci; David M Loeb
WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group.
Pediatric blood & cancer 2009;53(6):1136-9.
2009: Eric Schafer; Allen R Chen; Robert J Arceci
Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant.
Pediatric blood & cancer 2009;53(6):1127-9.
2009: Tanya M Trippett; Cynthia Herzog; James A Whitlock; Johannes Ernst Wolff; John Kuttesch; Rochelle Bagatell; Stephen P Hunger; Jessica Boklan; Amy A Smith; Robert J Arceci; Howard M Katzenstein; Christopher Harbison; Xiaofei Zhou; Haolan Lu; Christiane Langer; Martin Weber; Lia Gore
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5102-8.
2009: Sima Jeha; Bassem I Razzouk; Michael Rytting; Susan Rheingold; Edythe Albano; Richard Kadota; Lori Luchtman-Jones; Lisa R Bomgaars; Paul S Gaynon; Stewart Goldman; Kim Ritchey; Robert J Arceci; Arnold Altman; Kimo Stine; Laurel Steinherz; Peter G Steinherz
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4392-7.
2008: Robert J Arceci
Pediatric Blood & Cancer: the first 5 years.
Pediatric blood & cancer 2008;51(5):581-3.
2008: Toshikazu Suzuki; JASON FARRAR; Srinivasan Yegnasubramanian; Muhammed Zahed; Nobuo Suzuki; Robert J Arceci
Stable knockdown of PASG enhances DNA demethylation but does not accelerate cellular senescence in TIG-7 human fibroblasts.
Epigenetics : official journal of the DNA Methylation Society 2008;3(5):281-91.
2008: JASON FARRAR; Michelle Nater; Emi H Caywood; A MICHAEL MCDEVITT; Jeanne Kowalski; Clifford M Takemoto; C Conover Talbot; Paul Meltzer; Diane Esposito; Alan H Beggs; Hal E Schneider; Agnieszka Grabowska; Sarah E Ball; Edyta Niewiadomska; Colin A Sieff; Adrianna Vlachos; Eva Atsidaftos; Steven R Ellis; Jeffrey Lipton; Hanna T Gazda; Robert J Arceci
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia.
Blood 2008;112(5):1582-92.
2008: Robert J Arceci
When T cells and macrophages do not talk: the hemophagocytic syndromes.
Current opinion in hematology 2008;15(4):359-67.
2008: Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; Craig A Hurwitz; Robert J Wells; Irwin D Bernstein; Patrick Buckley; Kathleen Krimmel; Franklin O Smith; Eric L Sievers; Robert J Arceci
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2390-3295.
2008: Kirsten M Williams; Meghan A Higman; Allen R Chen; Cindy L Schwartz; Moody D Wharam; Paul M Colombani; Robert J Arceci
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Pediatric blood & cancer 2008;50(3):667-70.
2008: Gitanjali I Bechan; Alan K Meeker; Angelo M DeMarzo; Frederick Racke; Ronald Jaffe; Elizabeth Sugar; Robert J Arceci
Telomere length shortening in Langerhans cell histiocytosis.
British journal of haematology 2008;140(4):420-8.
2008: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia A Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita L Seibel; Margie Weiman; Kathryn E Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
Blood 2008;111(3):1044-53.
2008: Josh David Lauring; Abde M Abukhdeir; HIROYUKI KONISHI; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Blood 2008;111(2):856-64.
2008: Girish Dhall; Jonathan Lester Finlay; Ira J Dunkel; Lawrence J Ettinger; Stewart J Kellie; Jeffrey C Allen; R Maarten Egeler; Robert J Arceci
Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.
Pediatric blood & cancer 2008;50(1):72-9.
2007: Liyong Zhang; Michael S Anglesio; Maureen O'Sullivan; Fan Zhang; Ge Yang; Renu Sarao; P Nghiem Mai; Shane Cronin; Hiromitsu Hara; Nataliya Melnyk; Liheng Li; Teiji Wada; Peter P Liu; JASON FARRAR; Robert J Arceci; Poul H B Sorensen; Josef M Penninger
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.
Nature medicine 2007;13(9):1060-9.
2007: Patrick Brown; Emily McIntyre; Rachel Elizabeth Rau; Soheil Meshinchi; Norman J Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
Blood 2007;110(3):979-85.
2007: L Christine Turtzo; Doris D M Lin; Helge Hartung; Peter B Barker; Robert J Arceci; Kaleb Yohay
A neurologic presentation of familial hemophagocytic lymphohistiocytosis which mimicked septic emboli to the brain.
Journal of child neurology 2007;22(7):863-8.
2007: Rochelle Bagatell; Lia Gore; Merrill J Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G Zuhowski; James A Whitlock; Stephen P Hunger; Aru Narendran; Howard M Katzenstein; Robert J Arceci; Jessica Boklan; Cynthia E Herzog; Luke Whitesell; S Percy Ivy; Tanya M Trippett
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1783-8.
2007: Draga Barbaric; Todd A Alonzo; Robert B Gerbing; Soheil Meshinchi; Nyla A Heerema; Dorothy R Barnard; Beverly J Lange; William G Woods; Robert J Arceci; Franklin O Smith
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
Blood 2007;109(6):2314-21.
2007: Soheil Meshinchi; Robert J Arceci
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
The oncologist 2007;12(3):341-55.
2007: Frederick R Appelbaum; Daniel Rosenblum; Robert J Arceci; William L Carroll; Philip P Breitfeld; Stephen J Forman; Richard A Larson; Stephanie J Lee; Sharon B Murphy; Susan O'Brien; Jerald P Radich; Nancy S Scher; Franklin O Smith; Richard M Stone; Martin S Tallman
End points to establish the efficacy of new agents in the treatment of acute leukemia.
Blood 2007;109(5):1810-6.
2007: Denise M Oliansky; J Douglas Rizzo; Peter D Aplan; Robert J Arceci; Louis Leone; Yaddanapudi Ravindranath; Jean E Sanders; Franklin O Smith; Fiona Wilmot; Philip L McCarthy; Theresa Hahn
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(1):1-25.
2006: Soheil Meshinchi; Robert J Arceci; Jean E Sanders; Franklin O Smith; William B Woods; Jerald P Radich; Todd A Alonzo
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
Blood 2006;108(1):400; author reply 400-1.
2006: George R Kim; Allen R Chen; Robert J Arceci; Sandra H Mitchell; K Michelle Kokoszka; Denise Daniel; Christoph U Lehmann
Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis.
Archives of pediatrics & adolescent medicine 2006;160(5):495-8.
2006: Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven D Weitman; Peter G Steinherz
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1917-23.
2006: David L Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Frederick G. Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir I Sikic; Robert J Arceci; Howard Weinstein
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
Blood 2006;107(4):1315-24.
2006: Robert J Arceci
Surviving childhood cancer: a special series on the successes and challenges after "cure".
Pediatric blood & cancer 2006;46(2):119-21.
2006: BRIGITTE WIDEMANN; Wanda L Salzer; Robert J Arceci; Susan M Blaney; Elizabeth Fox; David W End; Andrea Gillespie; Patricia Whitcomb; Joseph S Palumbo; Aaron Pitney; Nalini Jayaprakash; Peter Zannikos; FRANK BALIS
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):507-16.
2006: G I Bechan; R Maarten Egeler; Robert J Arceci
Biology of Langerhans cells and Langerhans cell histiocytosis.
International review of cytology 2006;254():1-43.
2005: F O Smith; Todd A Alonzo; Robert B Gerbing; William G Woods; Robert J Arceci
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.
Leukemia 2005;19(12):2054-62.
2005: Robert J Arceci; Jane Sande; Beverly Lange; Kevin Shannon; Janet Franklin; Raymond J Hutchinson; Terry A Vik; David A Flowers; Richard Aplenc; Mark S Berger; Matthew L Sherman; Franklin O Smith; Irwin D Bernstein; Eric L Sievers
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Blood 2005;106(4):1183-8.
2005: Peter C L Beverley; R Maarten Egeler; Robert J Arceci; Jon Pritchard
The Nikolas Symposia and histiocytosis.
Nature reviews. Cancer 2005;5(6):488-94.
2005: Andrew L Feldman; Frank Berthold; Robert J Arceci; Carlos Abramowsky; Bahig M Shehata; Karen P Mann; Stephen J Lauer; Jon Pritchard; Mark Raffeld; Elaine S Jaffe
Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis.
The lancet oncology 2005;6(6):435-7.
2005: John J Strouse; MELISSA SPEVAK; A Kyle Mack; Robert J Arceci; Donald Small; David M Loeb
Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Pediatric blood & cancer 2005;44(4):407-11.
2005: Lin-Quan Sun; Robert J Arceci
Altered epigenetic patterning leading to replicative senescence and reduced longevity. A role of a novel SNF2 factor, PASG.
Cell cycle (Georgetown, Tex.) 2005;4(1):3-5.
2004: Patrick Brown; Soheil Meshinchi; Mark Levis; Todd A Alonzo; Robert B Gerbing; Beverly Lange; Robert J Arceci; Donald Small
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Blood 2004;104(6):1841-9.
2004: Robert J Arceci
The art and science of writing manuscripts.
Pediatric blood & cancer 2004;43(3):207-10.
2004: Robert J Arceci; Max J Coppes
Challenge of curing cancer worldwide--two ends of the spectrum.
Pediatric blood & cancer 2004;43(2):97-8.
2004: Robert J Arceci; Malcolm Smith
The changing face of clinical trials.
Pediatric blood & cancer 2004;43(1):1-3.
2004: Robert J Arceci
The challenges of cancer survivorship.
Pediatric blood & cancer 2004;42(7):553.
2004: Lin-Quan Sun; David W Lee; Quangeng Zhang; Weihong Xiao; Eric Hutton Raabe; Alan K Meeker; Dengshun Miao; David L Huso; Robert J Arceci
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG.
Genes & development 2004;18(9):1035-46.
2003: Marianne E Greene; Gina Mundschau; Joshua Wechsler; A MICHAEL MCDEVITT; Alan S Gamis; Judith E Karp; Sandeep Gurbuxani; Robert J Arceci; John D Crispino
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Blood cells, molecules & diseases 2003;31(3):351-6.
2003: Robert J Arceci
Response in osteosarcoma. Information you can't use...yet?
Journal of pediatric hematology/oncology 2003;25(11):837-8.
2003: Soheil Meshinchi; Franklin O Smith; Robert J Arceci
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
Current oncology reports 2003;5(6):489-97.
2003: Robert I Liem; Meghan A Higman; Allen R Chen; Robert J Arceci
Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children.
Journal of pediatric hematology/oncology 2003;25(10):818-21.
2003: Robert J Arceci
The challenge and cost of patient safety.
Journal of pediatric hematology/oncology 2003;25(10):757-8.
2003: Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Quangeng Zhang; David A Sweetser; William G Woods; Irwin D Bernstein; Robert J Arceci; Jerald P Radich
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
Blood 2003;102(4):1474-9.
2003: Robert J Wells; Mary T Adams; Todd A Alonzo; Robert J Arceci; Jonathan Buckley; Allen B Buxton; Kathryn E Dusenbery; Alan S Gamis; Margaret Masterson; Terry Vik; Phyllis Warkentin; James A Whitlock
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2940-7.
2003: Gina Mundschau; Sandeep Gurbuxani; Alan S Gamis; Marianne E Greene; Robert J Arceci; John D Crispino
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Blood 2003;101(11):4298-300.
2003: Robert J Arceci
Predicting outcomes--not as easy as it looks.
Journal of pediatric hematology/oncology 2003;25(5):347.
2003: Eric L Sievers; Beverly J Lange; Todd A Alonzo; Robert B Gerbing; Irwin D Bernstein; Franklin O Smith; Robert J Arceci; William G Woods; Michael R Loken
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Blood 2003;101(9):3398-406.
2003: Robert J Arceci
Robbing Peter to pay Paul? Financial reimbursement for chemotherapy.
Journal of pediatric hematology/oncology 2003;25(4):277-8.
2003: Kim E Nichols; R Maarten Egeler; V Hugh Perry; Robert J Arceci
Summary of the 12th Nikolas Symposium dendritic cell differentiation: signals, signaling and functional consequences as clues to possible therapy.
Journal of pediatric hematology/oncology 2003;25(3):193-7.
2003: Robert J Arceci
Comments from the editor-in-chief. Infectious complications of cancer treatment. Survivorship and treatment-related toxicities: how well are we doing?
Journal of pediatric hematology/oncology 2003;25(3):183.
2003: Robert J Arceci
Comments from the editor-in-chief.
Journal of pediatric hematology/oncology 2003;25(2):97-8.
2003: Jennifer J Clark; Franklin O Smith; Robert J Arceci
Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies.
Current opinion in hematology 2003;10(1):31-9.
2002: Robert J Arceci; Timothy P Cripe
Emerging cancer-targeted therapies.
Pediatric clinics of North America 2002;49(6):1339-68, vii-viii.
2002: Robert J Arceci
Comments from the Editor-in-Chief.
Journal of pediatric hematology/oncology 2002;24(9):697-9.
2002: Robert J Arceci; Alice Ettinger; Edwin Forman; Gerald M Haase; G Denman Hammond; Rutht Hoffman; Mary Jo Kupst; Michael P Link; Craig P Lustig; Dianne S Traynor
National action plan for childhood cancer: report of the national summit meetings on childhood cancer.
CA: a cancer journal for clinicians 2002;52(6):377-9.
2002: Robert J Arceci
Comments From the Editor-in-Chief.
Journal of pediatric hematology/oncology 2002;24(6):423.
2002: David M Loeb; Robert J Arceci
What is the optimal therapy for childhood AML?
Oncology (Williston Park, N.Y.) 2002;16(8):1057-66; discussion 1066, 1068-70.
2002: Allen R Chen; Todd A Alonzo; William G Woods; Robert J Arceci
Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view.
British journal of haematology 2002;118(2):378-84.
2002: Robert J Arceci
Progress and controversies in the treatment of pediatric acute myelogenous leukemia.
Current opinion in hematology 2002;9(4):353-60.
2002: David M Loeb; Robert J Arceci
Treatment and outcome of infants with acute myeloid leukemia.
Blood 2002;99(7):2626-7.
2002: Robert J Arceci
Testing new agents: can we move beyond DLT?
Journal of pediatric hematology/oncology 2002;24(2):83.
2002: John Gregory; Robert J Arceci
Acute myeloid leukemia in children: a review of risk factors and recent trials.
Cancer investigation 2002;20(7-8):1027-37.
2002: Robert J Arceci; B Jack Longley; Peter D Emanuel
Atypical cellular disorders.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():297-314.
2002: Robert J Arceci
Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia.
Journal of pediatric hematology/oncology 2002;24(1):1.
2001: Robert J Arceci
Clinical trials and tribulations.
Journal of pediatric hematology/oncology 2001;23(9):563.
2001: ZQ Ning; J Li; M McGuinness; Robert J Arceci
STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Oncogene 2001;20(33):4528-36.
2001: ZQ Ning; J Li; Robert J Arceci
Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
Blood 2001;97(11):3559-67.
2001: ZQ Ning; J Li; Robert J Arceci
Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.
Leukemia & lymphoma 2001;41(5-6):513-22.
2001: Eric Hutton Raabe; L Abdurrahman; Gregory K Behbehani; Robert J Arceci
An SNF2 factor involved in mammalian development and cellular proliferation.
Developmental dynamics : an official publication of the American Association of Anatomists 2001;221(1):92-105.
2001: Henrietta Nagy; Katalin Goda; Robert J Arceci; Maurizio Cianfriglia; Eugene Mechetner; Gábor Szabó
P-Glycoprotein conformational changes detected by antibody competition.
European journal of biochemistry / FEBS 2001;268(8):2416-20.
2001: Edward H Abraham; B Shrivastav; Anna Y Salikhova; Kenneth M Sterling; N Johnston; G Guidotti; S Scala; Thomas Litman; K C Chan; Robert J Arceci; K Steiglitz; L Herscher; P Okunieff
Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes.
Blood cells, molecules & diseases 2001;27(1):181-200.
2000: Robert J Wells; William G Woods; Jonathan D Buckley; Robert J Arceci
Therapy for acute myeloid leukemia: intensive timing of induction chemotherapy.
Current oncology reports 2000;2(6):524-8.
2000: Robert J Arceci
Unconventional therapies: "eyes wide shut".
Journal of pediatric hematology/oncology 2000;22(5):397.
2000: Robert J Arceci
Fever and neutropenia: changing patterns of medical practice.
Journal of pediatric hematology/oncology 2000;22(5):397.
2000: Robert J Arceci
Can multidrug resistance mechanisms be modified?
British journal of haematology 2000;110(2):285-91.
2000: D W Lee; K Zhang; Z Q Ning; Eric Hutton Raabe; S Tintner; R Wieland; B J Wilkins; J M Kim; RI Blough; Robert J Arceci
Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia.
Cancer research 2000;60(13):3612-22.
2000: Gary V Dahl; Norman J Lacayo; N Brophy; K Dunussi-Joannopoulos; Howard J Weinstein; M Chang; Branimir I Sikic; Robert J Arceci
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1867-75.
2000: Katalin Goda; Henrietta Nagy; László Bene; Margit Balázs; Robert J Arceci; Eugene Mechetner; Gábor Szabó
Conformational heterogeneity of P-glycoprotein.
Cancer detection and prevention 2000;24(5):415-21.
1999: M Aricò; K Nichols; J A Whitlock; Robert J Arceci; R Haupt; U Mittler; T Kühne; A Lombardi; E Ishii; R M Egeler; C Danesino
Familial clustering of Langerhans cell histiocytosis.
British journal of haematology 1999;107(4):883-8.
1999: Sheila Weitzman; ALAN WAYNE; Robert J Arceci; Jeffrey Lipton; J A Whitlock
Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature.
Medical and pediatric oncology 1999;33(5):476-81.
1999: F Huang; Robert J Arceci
The histiocytoses of infancy.
Seminars in perinatology 1999;23(4):319-31.
1999: J E Sande; Robert J Arceci; BC Lampkin
Congenital and neonatal leukemia.
Seminars in perinatology 1999;23(4):274-85.
1999: Robert J Arceci
The histiocytoses: the fall of the Tower of Babel.
European journal of cancer (Oxford, England : 1990) 1999;35(5):747-67; discussion 767-9.
1999: Robert J Arceci
Comments from the Editor-in-Chief.
Journal of pediatric hematology/oncology 1999;21(1):1-2.
1998: D M Bradshaw; Robert J Arceci
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3674-90.
1998: B J Sleight; V S Prasad; C DeLaat; Paul E Steele; Edgar T Ballard; Robert J Arceci; CL Sidman
Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation.
Bone marrow transplantation 1998;22(4):375-80.
1998: Hélène Paradis; Robert J Arceci; LC Adams; Robert L Gendron
Differentiation responses of embryonic endothelium to leukemia inhibitory factor.
Experimental cell research 1998;240(1):7-15.
1998: Robert J Arceci; M K Brenner; J Pritchard
Controversies and new approaches to treatment of Langerhans cell histiocytosis.
Hematology/oncology clinics of North America 1998;12(2):339-57.
1998: Robert J Arceci; G H Reaman; A R Cohen; BC Lampkin
Position statement for the need to define pediatric hematology/oncology programs: a model of subspecialty care for chronic childhood diseases. Health Care Policy and Public Issues Committee of the American Society of Pediatric Hematology/Oncology.
Journal of pediatric hematology/oncology 1998;20(2):98-103.
1998: Robert J Arceci
The potential for antitumor vaccination in acute myelogenous leukemia.
Journal of molecular medicine (Berlin, Germany) 1998;76(2):80-93.
1997: K Dunussi-Joannopoulos; Howard J Weinstein; Robert J Arceci; JM Croop
Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.
Journal of pediatric hematology/oncology 1997;19(6):536-40.
1997: M Visser; C Sijmons; Johannes Bras; Robert J Arceci; Marc B Godfried; Linda J Valentijn; Paul A Voûte; Frank Baas
Allelotype of pediatric rhabdomyosarcoma.
Oncogene 1997;15(11):1309-14.
1997: Kenneth E Rosenzweig; Robert J Arceci; N J Tarbell
Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?
Medical and pediatric oncology 1997;29(1):36-40.
1996: S Zhao; U Consoli; Robert J Arceci; J Pfeifer; W S Dalton; Michael Andreeff
Semi-automated PCR method for quantitating MDR1 expression.
BioTechniques 1996;21(4):726-31.
1996: B Li; Bin Ouyang; H Pan; P T Reissmann; Dennis J Slamon; Robert J Arceci; L Lu; W Dai
Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas.
The Journal of biological chemistry 1996;271(32):19402-8.
1996: Paula E Cohen; O Chisholm; Robert J Arceci; E Richard Stanley; Jeffrey W Pollard
Absence of colony-stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice results in male fertility defects.
Biology of reproduction 1996;55(2):310-7.
1996: D Martinez-Perez; John B Mulliken; Robert J Arceci
Langerhans cell histiocytosis: an uncommon disease commonly manifesting in the craniofacial skeleton.
Plastic and reconstructive surgery 1996;98(2):211-6.
1996: Robert L Gendron; F Y Tsai; Hélène Paradis; Robert J Arceci
Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo.
Developmental biology 1996;177(1):332-46.
1996: Robert J Arceci
Tumor cell survival and resistance to therapy.
Current opinion in hematology 1996;3(4):279-87.
1996: U Utans; W C Quist; Bruce M McManus; J E Wilson; Robert J Arceci; A F Wallace; Mary E Russell
Allograft inflammatory factory-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts.
Transplantation 1996;61(9):1387-92.
1996: K Dunussi-Joannopoulos; Howard J Weinstein; P W Nickerson; T B Strom; Steven J Burakoff; JM Croop; Robert J Arceci
Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.
Blood 1996;87(7):2938-46.
1996: D C Mangham; A Cannon; Setsuro Komiya; Robert L Gendron; K Dunussi; M C Gebhardt; Henry J Mankin; Robert J Arceci
P-glycoprotein is expressed in the mineralizing regions of the skeleton.
Calcified tissue international 1996;58(3):186-91.
1995: R O'Connor; C Liu; C A Ferris; B C Guild; B A Teicher; C Corvi; Y Liu; Robert J Arceci; Victor S Goldmacher; J M Lambert; W A Blättler
Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.
Blood 1995;86(11):4286-94.
1995: Robert J Arceci
Mechanisms of resistance to therapy and tumor cell survival.
Current opinion in hematology 1995;2(4):268-74.
1995: U Utans; Robert J Arceci; Y Yamashita; Mary E Russell
Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection.
The Journal of clinical investigation 1995;95(6):2954-62.
1995: R Kramer; T K Weber; Robert J Arceci; N Ramchurren; W V Kastrinakis; Glenn Steele; I C Summerhayes
Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.
British journal of cancer 1995;71(4):670-5.
1994: Robert J Arceci
Treatment options--commentary.
The British journal of cancer. Supplement 1994;23():S58-60.
1994: Mary E Russell; U Utans; A F Wallace; P Liang; Robert J Arceci; Morris J Karnovsky; L R Wyner; Y Yamashita; C Tarn
Identification and upregulation of galactose/N-acetylgalactosamine macrophage lectin in rat cardiac allografts with arteriosclerosis.
The Journal of clinical investigation 1994;94(2):722-30.
1994: X P Zhang; M K Ritke; Jack C Yalowich; Marilyn L Slovak; J P Ho; K I Collins; T Annable; Robert J Arceci; F E Durr; Lee M Greenberger
P-glycoprotein mediates profound resistance to bisantrene.
Oncology research 1994;6(7):291-301.
1993: Alfred H Schinkel; Robert J Arceci; J J Smit; Els Wagenaar; F Baas; M Dollé; T Tsuruo; Eugene Mechetner; Igor B Roninson; Piet Borst
Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.
International journal of cancer. Journal international du cancer 1993;55(3):478-84.
1993: R Kramer; T K Weber; Robert J Arceci; B Morse; H Simpson; Glenn Steele; I C Summerhayes
Modulation of mdr-1 expression by a H-ras oncogene in a human colon carcinoma cell line.
International journal of cancer. Journal international du cancer 1993;54(2):275-81.
1993: D Filocoma; H L Needleman; Robert J Arceci; R D Gelber; M Donnelly
Pediatric histiocytosis. Characterization, prognosis, and oral involvement.
The American journal of pediatric hematology/oncology 1993;15(2):226-30.
1993: R Kramer; T K Weber; B Morse; Robert J Arceci; R Staniunas; Glenn Steele; I C Summerhayes
Constitutive expression of multidrug resistance in human colorectal tumours and cell lines.
British journal of cancer 1993;67(5):959-68.
1993: Robert J Arceci
Clinical significance of P-glycoprotein in multidrug resistance malignancies.
Blood 1993;81(9):2215-22.
1993: Robert J Arceci; A A King; M C Simon; Stuart H Orkin; D B Wilson
Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart.
Molecular and cellular biology 1993;13(4):2235-46.
1993: Robert J Arceci; K Stieglitz; J Bras; Alfred H Schinkel; F Baas; JM Croop
Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein.
Cancer research 1993;53(2):310-7.
1993: B N Cao; B S Huneycutt; C P Gapud; Robert J Arceci; Carol Shoshkes Reiss
Lymphokine expression profile of resting and stimulated CD4+ CTL clones specific for the glycoprotein of vesicular stomatitis virus.
Cellular immunology 1993;146(1):147-56.
1993: E H Abraham; A G Prat; L Gerweck; T Seneveratne; Robert J Arceci; R Kramer; G Guidotti; Horacio F Cantiello
The multidrug resistance (mdr1) gene product functions as an ATP channel.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(1):312-6.
1992: Robert J Arceci; K Stieglitz; B E Bierer
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.
Blood 1992;80(6):1528-36.
1992: E Buschman; Robert J Arceci; JM Croop; M Che; I M Arias; D E Housman; Philippe Gros
mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies.
The Journal of biological chemistry 1992;267(25):18093-9.
1992: Robert J Arceci; S Pampfer; Jeffrey W Pollard
Expression of CSF-1/c-fms and SF/c-kit mRNA during preimplantation mouse development.
Developmental biology 1992;151(1):1-8.
1992: Richard T Maziarz; Robert J Arceci; S C Bernstein; Lindsay Frazier; Brian R Smith; M Kasai; R Tantravahi; Jack L Strominger
A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity.
Blood 1992;79(6):1523-31.
1992: Roberto Mazzanti; JM Croop; Z Gatmaitan; M Budding; K Steiglitz; Robert J Arceci; I M Arias
Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells.
Oncology research 1992;4(8-9):359-65.
1991: S Pampfer; Robert J Arceci; Jeffrey W Pollard
Role of colony stimulating factor-1 (CSF-1) and other lympho-hematopoietic growth factors in mouse pre-implantation development.
BioEssays : news and reviews in molecular, cellular and developmental biology 1991;13(10):535-40.
1990: F Baas; A P Jongsma; Henk J Broxterman; Robert J Arceci; D Housman; George L Scheffer; A Riethorst; Marjon van Groenigen; A W Nieuwint; Hans Joenje
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Cancer research 1990;50(17):5392-8.
1990: Robert J Arceci; F Baas; R Raponi; Susan B. Horwitz; D Housman; JM Croop
Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus.
Molecular reproduction and development 1990;25(2):101-9.
1989: Lee M Greenberger; JM Croop; Susan B. Horwitz; Robert J Arceci
P-glycoproteins encoded by mdr 1b in murine gravid uterus and multidrug resistant tumor cell lines are differentially glycosylated.
FEBS letters 1989;257(2):419-21.
1989: Robert J Arceci; F Shanahan; E Richard Stanley; Jeffrey W Pollard
Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(22):8818-22.
1989: J Z Wimperis; C M Niemeyer; Colin A Sieff; Bernard Mathey-Prevot; David G Nathan; Robert J Arceci
Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells.
Blood 1989;74(5):1525-30.
1989: Jyoti Misra Sen; Robert J Arceci; W Jones; Steven J Burakoff
Expression and ontogeny of murine CD2.
European journal of immunology 1989;19(7):1297-302.
1989: JM Croop; M Raymond; D Haber; A Devault; Robert J Arceci; Philippe Gros; D E Housman
The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.
Molecular and cellular biology 1989;9(3):1346-50.
1989: Chia-Ping Huang Yang; S G DePinho; Lee M Greenberger; Robert J Arceci; Susan B. Horwitz
Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.
The Journal of biological chemistry 1989;264(2):782-8.
1988: Robert J Arceci; JM Croop; Susan B. Horwitz; D Housman
The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(12):4350-4.
1987: Jeffrey W Pollard; A Bartocci; Robert J Arceci; Amos Orlofsky; M B Ladner; E Richard Stanley
Apparent role of the macrophage growth factor, CSF-1, in placental development.
Nature 1987;330(6147):484-6.
1987: R Zeller; K D Bloch; B S Williams; Robert J Arceci; C E Seidman
Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis.
Genes & development 1987;1(7):693-8.
1986: C J Beard; L Lyndon Key; P E Newburger; R A Ezekowitz; Robert J Arceci; B Miller; P Proto; T Ryan; C Anast; Elizabeth R Simons
Neutrophil defect associated with malignant infantile osteopetrosis.
The Journal of laboratory and clinical medicine 1986;108(5):498-505.
1986: J H Antin; B R Smith; B M Ewenstein; Robert J Arceci; Jeffrey Lipton; P L Page; J M Rappeport
HTLV-III infection after bone marrow transplantation.
Blood 1986;67(1):160-3.
1984: L Lyndon Key; D Carnes; S Cole; M Holtrop; Z Bar-Shavit; Frederic Shapiro; Robert J Arceci; J Steinberg; C Gundberg; A Kahn
Treatment of congenital osteopetrosis with high-dose calcitriol.
The New England journal of medicine 1984;310(7):409-15.
1980: Robert J Arceci; P R Gross
Sea urchin sperm chromatin structure as probed by pancreatic DNase I: evidence for a noval cutting periodicity.
Developmental biology 1980;80(1):210-24.
1980: Robert J Arceci; P R Gross
Histone variants and chromatin structure during sea urchin development.
Developmental biology 1980;80(1):186-209.
1980: Robert J Arceci; P R Gross
Histone gene expression: progeny of isolated early blastomeres in culture make the same change as in the embryo.
Science (New York, N.Y.) 1980;209(4456):607-9.
1978: D R Senger; Robert J Arceci; P R Gross
Histones of sea urchin embryos. Transients in transcription, translation, and the composition of chromatin.
Developmental biology 1978;65(2):416-25.
1977: Robert J Arceci; P R Gross
Noncoincidence of histone and DNA synthesis in cleavage cycles of early development.
Proceedings of the National Academy of Sciences of the United States of America 1977;74(11):5016-20.
1976: Robert J Arceci; D R Senger; P R Gross
The programmed switch in lysine-rich histone synthesis at gastrulation.
Cell 1976;9(1):171-8.
1974: D B Galbraith; Robert J Arceci
Melanocyte populations of yellow and black hair bulbs in the mouse.
The Journal of heredity 1974;65(6):381-2.